Roche’s automated p-tau217 blood test showed high accuracy for detecting brain amyloid pathology in a Taiwanese memory clinic cohort, placing 88.1% of participants into definitive result zones. The study supports a more operational approach to amyloid stratification using standardized laboratory workflows, potentially reducing reliance on less certain borderline imaging or repeat testing. For biotech and diagnostics, the key commercial angle is workflow readiness: automated triage is a step toward broader scaling of amyloid confirmation pathways that can streamline downstream trial enrollment and patient management decisions.